We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Microbubble Technology Releases Oxygen on Demand

By HospiMedica International staff writers
Posted on 06 Aug 2021
A stable polymeric microbubble (MB) platform that releases Oxygen (O2) on demand could help prevent blood clotting during dialysis and blood oxidation therapies.

The Inspira Technologies (Ra'anana, Israel) MB platform, which was developed in conjunction with Ben-Gurion University (BGU; Beer Sheva), integrates into the Augmented Respiration Technology (ART) 500, a compact extracorporeal blood oxygenation system that is designed to oxygenate one liter of blood in one minute, rebalancing a patients' O2 saturation levels to a safe level of 95% or higher while they are awake and mobile, thus preventing the need for medically induced comas and intubation.

Image: The Augmented Respiration Technology (ART) 500 system (Photo courtesy of Inspira Technologies)
Image: The Augmented Respiration Technology (ART) 500 system (Photo courtesy of Inspira Technologies)

The polymeric MBs include an O2 gas core and a polylactic-co-glycolic acid (PLGA) shell synthesized by a modified double emulsion solvent evaporation method. As the MBs release their O2 load on demand, they can be used extend the life of oxidizers, thus potentially preventing the blood clotting resulting from required anticoagulant use during invasive O2 therapy. While still under development, MB technology (once fully integrated into the ART system), could be suitable to serve as an adjunct to dialysis and compatible with other blood oxidation systems.

“The use of anticoagulants for preventing blood clotting during invasive oxygen therapy is standard procedure, despite these drugs posing a high risk,” said Udi Nussinovitch, MD, PhD, Co-Founder and chief scientific officer of Inspira. “The joined technologies are intended to use innovative molecular approaches and novel oxygenation methods that have the potential to improve patients' outcomes.”

Oxygen saturation (SpO2) is the fraction of O2-saturated hemoglobin relative to total hemoglobin in the blood, with normal arterial blood oxygen saturation levels in humans are 95–100%. If the level is below 90%, it is considered hypoxemia. SpO2 levels below 80% may compromise organ function, such as the brain and heart, and should be promptly addressed. Continued low oxygen levels may lead to respiratory or cardiac arrest.

Related Links:

Inspira Technologies
Ben-Gurion University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Transcatheter Heart Valve
SAPIEN 3 Ultra
New
Transducer Covers
Surgi Intraoperative Covers

Latest Critical Care News

Ablation Treatment Better Than Medication for Heart Attack Survivors

Cranial Accelerometry Headset Enables Timely and Accurate Prehospital Detection of LVO Strokes

Ingestible Capsule Pump Drugs Directly into Walls of GI Tract